Potassium supplements during long-term thiazide therapy for essential hypertension

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Clinical Pharmacology

Background:

• Hypertension management often involves diuretics like bendrofluazide, which can deplete potassium.
• Potassium supplementation is crucial for maintaining electrolyte balance and cardiovascular health in these patients.

Purpose of the Study:

• To evaluate the efficacy of slow-release potassium supplements in correcting hypokalemia in hypertensive patients.
• To determine if commonly prescribed doses achieve adequate potassium repletion.

Main Methods:

• Nine hypertensive patients on long-term bendrofluazide therapy received increasing doses of slow-release potassium.
• Serum potassium and total body potassium (TBK) were measured at 2-month intervals over a 6-month period.

Main Results:

• No significant increase in serum potassium levels was observed.
• Total body potassium (TBK) also showed no significant change throughout the supplementation period.
• The tested doses of slow-release potassium were insufficient to replete potassium levels.

Conclusions:

• Standard doses of slow-release potassium supplements are ineffective in significantly increasing potassium levels in hypertensive patients treated with bendrofluazide.
• Current supplementation strategies may require dose adjustment or alternative approaches for effective potassium management.